Pricing Log in Create free account
Saturday 17 October 2026 Export CVM’s income statement to Excel — free account

Cel-Sci Corporation

CVM Healthcare Biotechnology

In the quarter to June 2026, EPS grew 65.4%, free cash flow fell 2.33% and total debt fell 39.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

1.79 0.05 +2.87%
Market cap
$30.6M
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
−1.64
Beneish M
−2.35
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.87
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — 1 1 — — — 2 — — 1 — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 30.61
Revenue 0.56
Net Income (22.70)
Free Cash Flow (16.75)
Net Debt (2.74)
Current Ratio 1.48
Debt/Equity 0.35 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (12.20) (negative: loss-making)
P/S ratio 38.82 (above 10: high)
P/B ratio 1.98
Past 5Y EPS Growth —
This Y EPS Growth (16.20%) (below 0%: weak)
Next Y EPS Growth 22.39% (at or above 15%: strong)
Next Y revenue growth (100.00%) (below 0%: weak)
Next 5Y EPS Growth 25.29% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 35.0×, against a ten-year median of 186×; over the ten years it ranged from 18.7× in 2026 to 1,719× in 2021.
P/S against its own 10 years 7.78%
10-year low 10-year high
P/B against its own 10 years 9.47%
10-year low 10-year high
EV/Sales against its own 10 years 5.68%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 4 5 11 7
Receivables — — — —
Inventory 2 1 0 0
Other 0 0 0 0
7 6 12 8
2023 2024 2025 Q'26
Payables 2 1 1 1
ST’ Debt — — — —
Other — — — —
6 5 5 5

Compound Annual Growth %

10y 5y 3y
Sales 21.44% 16.18% 25.14%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (4.15%) (20.84%)

Revenue $m

Dec Mar Jun Sep Year
’26 — — — — —
’20 0 0 0 0 1
’19 0 0 0 0 0
’18 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Dec Mar Jun Sep Year
’26 (4) (4) (4) — —
’25 (4) (4) (4) (5) (17)
’24 (5) (5) (5) (5) (19)
’23 (5) (7) (6) (5) (23)
’22 (5) (3) (6) (5) (18)
’21 (4) (5) (5) (5) (19)
’20 (4) (4) (4) (4) (15)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Dec Mar Jun Sep Year
’26 (4) (4) (4) — —
’25 (4) (4) (4) (5) (17)
’24 (5) (5) (5) (5) (19)
’23 (5) (8) (6) (5) (23)
’22 (5) (3) (6) (5) (19)
’21 (7) (8) (7) (5) (28)
’20 (4) (5) (5) (5) (18)
Fiscal quarters ending in the months shown.

EPS $

Dec Mar Jun Sep Year
’26 (0.68) (0.67) (0.47) — —
’25 (3.30) (2.40) (1.36) 0.68 (6.27)
’24 (4.20) (4.20) (4.20) (2.70) (15.31)
’23 (5.41) (5.71) (5.71) (4.80) (21.92)
’22 (6.01) (6.91) (6.91) (6.31) (26.13)
’21 (6.31) (8.41) (7.51) (5.71) (27.93)
’20 (4.80) (7.51) (8.11) (4.20) (24.62)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to September

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 45.00 43.80 24.60 71.10 190.50 211.80 56.40 31.20 11.10 1.98

Analyst estimates 2026–2028

Powerpack
High 495.00 135.00 133.20 297.90 540.00 1,227.30 231.90 99.90 92.40 20.40
People
People Employees — — — — — — — — — —
Revenue/emp, $m 0.00 — 0.00 0.00 0.00 — — — — —
Income, $m
Income, $m Revenue 0 — 0 0 1 — — — — —
Gross margin, % 100.00 0.00 100.00 100.00 100.00 0.00 0.00 0.00 — —
EBT (12) (14) (32) (22) (30) (36) (37) (32) (27) (25)
EBT margin, % (4,038.06) 0.00 (6,680.07) (4,782.76) (5,415.30) 0.00 0.00 0.00 0.00 0.00
Net income (12) (14) (32) (22) (30) (36) (37) (32) (27) (25)
Depreciation 1 2 3 1 2 2 4 4 4 4
Per share, $
Per share, $ Revenue 1.76 0.00 0.84 0.45 0.46 0.00 0.00 0.00 0.00 0.00
Earnings (67.57) (54.95) (56.16) (21.32) (24.62) (27.03) (26.13) (21.92) (15.31) (6.27)
Cash flow (142.48) (52.48) (23.64) (15.72) (12.48) (13.88) (12.69) (15.43) (10.44) (4.22)
Capex (0.21) (0.06) (0.10) (0.32) (2.20) (6.68) (0.46) (0.25) (0.06) (0.01)
Free cash flow (142.70) (52.55) (23.75) (16.05) (14.68) (20.55) (13.15) (15.68) (10.50) (4.23)
Book value (4.19) (12.70) 0.00 4.95 16.12 41.75 22.38 8.92 7.14 3.93
Shares, m 0 0 1 1 1 1 1 1 2 4
Valuation, ×
Valuation, × P/E 0.00 — 0.00 0.00 0.00 — — — — —
P/S 132.11 — 151.85 601.73 838.05 — — — — —
P/B 0.00 — 80,414.60 54.23 23.74 — — — — —
EV/Sales 171.39 — 160.61 615.05 833.24 — — — — —
EV/FCF (2.11) — (5.69) (17.09) (25.90) — — — — —
Cash, $m
Cash, $m Operating cash flow (23) (14) (13) (16) (15) (19) (18) (23) (19) (17)
Capex 0 0 0 0 (3) (9) (1) 0 0 0
Free cash flow (23) (14) (13) (17) (18) (28) (19) (23) (19) (17)
Balance, $m
Balance, $m Working capital 1 (7) 2 7 13 41 21 1 1 6
Total debt 13 13 13 14 12 13 12 10 8 6
Net debt 10 11 3 5 (4) (29) (11) 6 3 (5)
Shareholders’ equity (1) (3) 0 5 20 57 32 13 13 16
Returns, %
Returns, % ROA (43.09) (60.35) (121.31) (77.38) (88.84) (63.08) (59.54) (79.86) (95.90) (92.16)
ROIC (157.00) (178.26) (341.36) (123.78) (113.43) (82.04) (106.25) (103.44) (102.38) (145.08)
ROE 423.14 718.45 1,909.51 (862.17) (243.58) (96.28) (84.85) (142.65) (211.49) (176.32)
Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2020 · latest quarter Sep 2020

Charts ten years each

Cel-Sci Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ALGS Aligos Therapeutics, Inc. $33.7M — (loss-making) — (loss-making) +2,778.55% (above 0%: growing) n/m −59.81% (below 0%: shrinking) 100.00% (6.80%) Compare
ATNM Actinium Pharmaceuticals, Inc. $33.3M 3.1× — (loss-making) +77,677.78% (above 0%: growing) n/m −4.91% (below 0%: shrinking) 100.00% 78.76% Compare
BCTX BRIACELL THERAP $32.8M 1.5× — — n/m +0.21% (above 0%: growing) 0.00% 0.00% Compare
GNTA Genenta Science S.p.A. Unsponsored ADR $32.3M — — — — +35.94% (above 0%: growing) 0.00% — Compare
MGX Metagenomi Therapeutics, Inc. $31.9M — (loss-making) — (loss-making) −103.02% (below 0%: shrinking) n/m +7.98% (above 0%: growing) 100.00% 11,195.72% Compare
GRDX GridAI Technologies Corp. $31.8M — (loss-making) — — n/m −2,640.98% (below 0%: shrinking) (42.49%) (15,258.21%) Compare
NXTC NextCure, Inc. $31.5M — (loss-making) — (loss-making) +1,549.08% (above 0%: growing) n/m +57.23% (above 0%: growing) 0.00% 0.00% Compare
CVM Cel-Sci Corporation $30.6M — (loss-making) — (loss-making) −62.66% (below 0%: shrinking) n/m −2.33% (below 0%: shrinking) 0.00% 0.00%
RNAZ TransCode Therapeutics Inc. $30.5M — (loss-making) — — n/m −28.79% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $32.1M — — +2,163.82% — −2.35% 0.00% 0.00%

All 614 Biotechnology stocks →

Cel-Sci Corporation (CVM) key facts

  • Cel-Sci Corporation (CVM) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
  • As of October 16, 2026, CVM traded at $1.79, a market capitalization of $30.6 million.
  • Return on equity was −176.3% and debt-to-equity 0.35.

Source: company filings (standardised) and stockrow calculations.

Cel-Sci Corporation (CVM) Latest News

16 May

Impact 5 ·
stockrow.com/CVM · Data as of Sep 30, 2020 · For information only; not investment advice. · © 2026 stockrow.com